Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
156 hedge funds and large institutions have $703M invested in Aerie Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 52 funds opening new positions, 47 increasing their positions, 45 reducing their positions, and 33 closing their positions.
99% more capital invested
Capital invested by funds: $354M → $703M (+$350M)
58% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 33
34% more call options, than puts
Call options by funds: $610K | Put options by funds: $454K
14% more funds holding
Funds holding: 137 → 156 (+19)
4% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIC
Water Island Capital
New York
|
+$24.2M |
| 2 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
+$18.4M |
| 3 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$12.5M |
| 4 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$12M |
| 5 |
Goldman Sachs
New York
|
+$9.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$17.7M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$15.1M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$11.4M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$9.24M |
| 5 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$8.67M |
AERI Hedge Fund Activity: Q3 2022 in Review
156 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2022, worth a combined $703M — up 99% from $354M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new AERI positions and 33 closed out — a net gain of 19 holders — while 47 added to existing stakes and 45 trimmed.
The largest buyer was Water Island Capital, opening a new position worth an estimated $24.2M. The largest seller was Bank of America, cutting an estimated $17.7M.
- 156 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2022, up from 137 in Q2 2022.
- Funds reported $703M of Aerie Pharmaceuticals stock for Q3 2022, up 99% quarter-over-quarter.
- 52 funds opened new Aerie Pharmaceuticals positions in Q3 2022 and 33 closed out, a net change of +19 holders.
- The largest Aerie Pharmaceuticals buyer in Q3 2022 was Water Island Capital, an estimated $24.2M added.
- The largest Aerie Pharmaceuticals seller in Q3 2022 was Bank of America, an estimated $17.7M sold.
Based on aggregated 13F filings for Q3 2022.